1. Home
  2. Companies
  3. Teligent, Inc.
  4. Financial Statements
  5. Income Statement
  6. General and Administrative Expenses
Teligent, Inc. logo
Teligent, Inc. TLGT

Teligent, Inc. General and Administrative Expenses 2011-2026 | TLGT

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.
What these expenses include
  • Salaries of administrative staff (executives, HR, accountants, legal personnel)
  • Office rent and utilities
  • Office equipment and IT infrastructure
  • Professional services (auditors, lawyers, consultants)
  • Insurance
  • General administrative travel and representation expenses
What the metric indicates
  • Cost control
    A high level of such expenses may indicate inefficient management or an overly complex structure
  • Profitability
    Reducing administrative expenses while maintaining stable revenue increases operating profit
  • Comparative analysis
    Investors can compare this metric as a percentage of revenue among companies in the same industry
  • Business flexibility
    Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Teligent, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - 23.4 M - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
23.4 M 23.4 M 23.4 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer General and Administrative Expenses Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
 		78.3 M - 2.43 % $ 254 M germanyGermany
Aquestive Therapeutics Aquestive Therapeutics
AQST
 		79.8 M $ 4.14 0.36 % $ 443 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
 		46.1 M $ 8.41 4.73 % $ 230 M israelIsrael
Ardelyx Ardelyx
ARDX
 		337 M $ 6.06 1.94 % $ 1.46 B usaUSA
argenx SE argenx SE
ARGX
 		308 M $ 752.35 0.79 % $ 25 B niderlandNiderland
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
 		275 M $ 23.83 0.85 % $ 3.03 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
 		17.4 M $ 2.65 -1.12 % $ 16.6 M usaUSA
I-Mab I-Mab
IMAB
 		900 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
 		1.4 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
 		16.2 M - 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
 		7.15 M - -13.47 % $ 169 M franceFrance
BioCardia BioCardia
BCDA
 		3.32 M $ 1.2 -0.04 % $ 8 M usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
 		266 M $ 9.6 6.37 % $ 1.98 B usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
 		4.95 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
 		4.66 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
 		89.7 M - -24.86 % $ 820 K usaUSA
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
 		714 M $ 9.48 -3.27 % $ 613 M usaUSA
BioVie BioVie
BIVI
 		8.57 M $ 1.45 2.09 % $ 2.14 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
 		63.1 M - - $ 86.2 M usaUSA
Advaxis Advaxis
ADXS
 		12.2 M - -9.65 % $ 45.9 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
 		37.4 M - - $ 10.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
 		5.92 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
 		11 M - -10.17 % $ 12.2 K usaUSA
AIkido Pharma AIkido Pharma
AIKI
 		23.8 M - 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
 		47.9 M - - $ 1.01 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
 		17 M - - $ 26.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
 		37.9 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
 		22.2 M - 0.23 % $ 488 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
 		4.31 M $ 2.32 4.98 % $ 908 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
 		25.8 M - - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
 		1.15 B $ 56.49 1.78 % $ 10.8 B usaUSA
BioNTech SE BioNTech SE
BNTX
 		286 M $ 92.3 1.23 % $ 27.2 B germanyGermany
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
 		12.7 M - 3.16 % $ 1.9 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
 		18 M - - $ 2.17 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
 		10.9 M - 10.36 % $ 9.8 M usaUSA
Anavex Life Sciences Corp. Anavex Life Sciences Corp.
AVXL
 		13.8 M $ 3.04 1.54 % $ 259 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
 		20.5 M $ 1.16 -2.12 % $ 14.2 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
 		99.3 M $ 4.54 9.54 % $ 683 M britainBritain
Cabaletta Bio Cabaletta Bio
CABA
 		29.6 M $ 3.2 7.94 % $ 322 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
 		3.05 M $ 3.21 4.56 % $ 6.98 B israelIsrael
Aravive Aravive
ARAV
 		13 M - -13.39 % $ 1.45 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
 		20.8 M $ 19.97 2.94 % $ 1.78 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
 		13.4 M - -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
 		19.8 M - -39.0 % $ 4.57 M usaUSA
Codexis Codexis
CDXS
 		47.1 M $ 1.97 7.97 % $ 172 M usaUSA
Cerus Corporation Cerus Corporation
CERS
 		80.9 M $ 1.91 2.42 % $ 364 M usaUSA
Cullinan Management Cullinan Management
CGEM
 		54.2 M $ 15.4 6.72 % $ 928 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
 		101 M $ 1.75 0.87 % $ 205 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
 		100 M - - $ 867 M germanyGermany
AstraZeneca PLC AstraZeneca PLC
AZN
 		15.2 B - - $ 96.9 B britainBritain